Reader TTS

GRAIL: REFLECTION: Real World Evidence for Learnings in Early Cancer Detection, a Clinical Practice Learning Program Galleri Screening study for multiple cancers This is a population study

that uses the Galleri blood test to check for the presence of cancer, as well as the type of cancer. This study looks to determine if the Galleri multi-cancer early detection test will

improve general health measures by checking for more than 50 cancers through a simple blood draw. For more information, please contact Stefanie Gonzalez, [email protected], Adam

Zoble, [email protected], ____________ NIGHTINGALE: CliNIcal Utility of ManaGement of Patients witH CT and LDCT Identified Pulmonary Nodules UsinG the Percepta NasAL Swab ClassifiEr – with

Familiarization Screening study for pulmonary nodule biomarkers This study is designed to develop a minimally-invasive test to better determine a person’s risk for lung cancer. Results may

allow doctors to either avoid unnecessary testing for individuals that are considered low risk or expedite testing for high risk Veterans.  For more information, please contact Precious

Leaks-Gutierrez [email protected], ______________ NOBLE: NOse Brushing for Lung Cancer Assessment in Epithelium Screening study for pulmonary nodule biomarkers    This study

is designed to develop a biomarker test to aid in monitoring a person’s risk for lung cancer risk instead of LDCT for nodules identified for long-term monitoring by CT. For more

information, please contact Precious Leaks-Gutierrez at [email protected], _________________ MIRATI: Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab

in patients with advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation Treatment study for advances metastatic cancer with KRAS G12C mutation The phase 2 portion of “MIRATI” is a

clinical study for patients with locally advanced non-small cell lung cancer that have the KRAS G12C mutation. The goal of this study is to evaluate safety and efficacy of the

investigational MRTX849 monotherapy, in combination with KEYTRUDA, as a potential first-line treatment for this type of lung cancer. For more information, please contact Precious

Leaks-Gutierrez at  [email protected],